Posted inCardiology news
Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies
This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comparable safety profiles.